Peptide News Digest

#Xinjiang

2 stories

Regulatory · View digest

House Select Committee on the Chinese Communist Party July 17 Response Deadline Arrives Tomorrow for Merck, AbbVie, Eli Lilly, Pfizer, and Bristol-Myers Squibb on Xinjiang-Region and Chinese Military Medical Center Trial Sites (June 29 Letters from Chair Rep. John Moolenaar); Updated Trial Counts Show Merck 224 China Studies Since 2005 (Including 31 Xinjiang and 40 Military-Hospital Trials), Eli Lilly 220-Plus Studies Since 2003 (11 Xinjiang + 16 Military 2016-2024), Pfizer 6 Xinjiang and 43 Military, AbbVie 17 Xinjiang and 16 Military

The House Select Committee on the Chinese Communist Party's July 17, 2026 response deadline arrives tomorrow for five drugmakers on records of clinical trials conducted at Xinjiang-region hospitals and Chinese military medical centers: Merck, AbbVie, Eli Lilly, Pfizer, and Bristol-Myers Squibb. Chair Rep. John Moolenaar (R-Michigan) sent letters on June 29 requesting due diligence, data protection processes, and standards at Chinese trial sites. Updated trial counts documented in the letters: Merck sponsored or collaborated on 224 clinical studies in China since 2005, including at least 31 trials involving Xinjiang-region hospitals and at least 40 trials involving Chinese military medical centers. Eli Lilly appears to have sponsored or collaborated on more than 220 clinical studies in China since 2003, with at least 11 Xinjiang-region trials and at least 16 military-medical-center trials between 2016 and 2024. Pfizer had at least 6 Xinjiang-region trials and 43 military-hospital trials. AbbVie had 17 Xinjiang and 16 military. Bristol-Myers Squibb's specific counts were not detailed in the summary but the company received the same request. Merck stated that patient safety and ethical integrity are foundational to its clinical research; Eli Lilly said it is reviewing the letter closely.

Regulatory · View digest

House Select Committee on the Chinese Communist Party July 17 Response Deadline Approaches One Week Out for Eli Lilly, Merck, AbbVie, Pfizer, and Bristol-Myers Squibb on Chinese Clinical Trial Sites (June 29 Letters from Chair Rep. John Moolenaar); Lilly Disclosed Sponsoring at Least 11 Trials in Xinjiang-Region Hospitals Plus at Least 16 Trials at Chinese Military Medical Centers Across Type 2 Diabetes, Heart Disease, Obesity, Alzheimer's, Axial Spondyloarthritis, Breast Cancer, Lupus, Alopecia, Crohn's Disease, and Additional Indications

The House Select Committee on the Chinese Communist Party (chaired by Rep. John Moolenaar, R-Michigan) faces its July 17 response deadline one week from tomorrow for five drugmakers under national-security investigation over clinical trials conducted at Chinese sites: Eli Lilly, Merck, AbbVie, Pfizer, and Bristol-Myers Squibb. The letters, first reported by Reuters, were dated June 29 and asked companies to provide details of due diligence, data protection processes, and other standards at their trial sites in China, with particular attention to the Xinjiang region and military hospitals. Eli Lilly disclosed sponsoring at least 11 trials at Xinjiang-region hospitals plus at least 16 trials at Chinese military medical centers and hospitals, across type 2 diabetes, heart disease, obesity, Alzheimer's disease, axial spondyloarthritis, breast cancer, lupus, alopecia, Crohn's disease, and additional indications. The committee said it has no evidence of company wrongdoing but cites potential ethical and national-security risks. The letters run parallel to the BIOSECURE Act framework, the June 30 STAT Pharmalittle preview of the probe, and industry warnings from Fierce Biotech that the scrutiny risks 'huge distraction and expense' for US biopharma.